Navigation Links
ViaCyte to Present at ISSCR 2016 Annual Meeting

SAN DIEGO, June 22, 2016 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced two presentations at ISSCR 2016 Annual Meeting.  ISSCR 2016, the Global Stem Cell Event, is taking place June 22nd to 25th at Moscone West in San Francisco. 


Details of the presentations are as follows:Event:

Focus Session: Tools for Basic and Applied Stem Cell Biology - Panel discussion on pluripotent stem cell-based therapiesSpeaker:

Dr. Kevin D'Amour, Vice President, Research, and Chief Scientific OfficerDate/Time:

June 22, 11:00 a.m. to 12:00 p.m. PDTPoster:

In vitro generation of insulin producing cells with insulin secretion kinetics and mitochondrial respiration similar to adult human islets [Poster T2190]Speaker:

Dr. Alireza Rezania, Senior Director, DiscoveryDate/Time:

June 23, 7:00 p.m. to 8:00 p.m., PDTThe work on insulin-producing cells with characteristics of mature human beta cells that is being reported in the poster presentation originated within the Janssen BetaLogics group.  In February 2016, the assets of the Janssen BetaLogics group were consolidated into ViaCyte.

"The results being presented at ISSCR demonstrate the continued progress we are making towards the development of important new treatments for insulin-dependent diabetes," said Paul Laikind, PhD, President and CEO of ViaCyte.  "In particular, Dr. Rezania, who joined us as part of the BetaLogics asset consolidation, is reporting on advances that further bolster our leadership position in the field of stem cell-derived cell replacement therapy."

For more information about ViaCyte's participation in industry events, please visit:

About ViaCyteViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to reduce the risk of hypoglycemia and diabetes-related complications.  ViaCyte's product candidates are based on the derivation of pancreatic progenitor cells, which are then implanted in a durable and retrievable encapsulation device.  Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels.  ViaCyte has two products in development.  PEC-Direct product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients that have severe hypoglycemic episodes, extreme glycemic lability, and/or impaired awareness of hypoglycemia.  The PEC-EnCap (formerly VC-01™) product candidate delivers pancreatic progenitor cells in an immunoprotective device and is currently being evaluated in a Phase 1/2 trial in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function.  ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. 

For more information on the clinical trial, called STEP ONE, please visit

For more information on ViaCyte, please visit and connect with ViaCyte here: and

Logo -


To view the original version on PR Newswire, visit:

SOURCE ViaCyte, Inc.
Copyright©2016 PR Newswire.
All rights reserved

Related biology technology :

1. ViaCyte Granted Over 20 Patents in 2013 Further Establishing the Company as a Leader in the Field of Regenerative Medicine
2. ViaCyte to Present at 35th Annual Cowen and Company Health Care Conference
3. ViaCyte Acquires Rights to BetaLogics Assets, Expanding and Extending Industry-Leading Portfolio for Stem Cell-Derived Approaches to Type 1 Diabetes
4. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
5. Positive Clinical Breast Cancer Data Presented for NuView’s Molecular Imaging Biomarker NLS-VPAC1
6. Washington State University to Present on Tin Nanoneedles: A Technology for Lithium-ion Batteries, at Knowledge Foundation’s Next Generation Batteries 2013 Conference
7. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
8. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
9. Palatin Technologies To Present At The 25th Annual ROTH Conference
10. De nouvelles données mettent en évidence le fardeau considérable que représente la nycturie
11. 3D Biomatrix Announces Stipend to Present at Spring 2013 Conferences
Post Your Comments:
(Date:5/31/2019)... ... May 29, 2019 , ... For many years, the primary forms of cancer ... breakthrough therapies. Advances in immuno-oncology have led to the advent of Chimeric Antigen Receptor ... T cell receptors known as “CARs”. The CAR enables the final product to produce ...
(Date:5/22/2019)... NEW YORK (PRWEB) , ... May 22, 2019 , ... ... it has closed a $8 million Series A funding round co-led by Astanor ... State’s Empire State Development Fund and iSelect Fund . The company ...
(Date:5/14/2019)... Calif. (PRWEB) , ... May 14, 2019 , ... ... office expansion, effectively doubling its space from 2,500 to 5,000 square feet. , ... Early Gender DNA tests ,” says Gateway Genomics CEO, Chris Jacob. “The SneakPeek At-Home ...
(Date:5/2/2019)... ... April 30, 2019 , ... ... for Standardization ISO 9001:2015 standard, REPROCELL USA Inc. has demonstrated its ability ... addition, REPROCELL USA Inc. aims to enhance customer satisfaction through the effective ...
Breaking Biology Technology:
(Date:5/23/2019)... ... May 23, 2019 , ... Federal Publications Seminars, the ... is pleased to announce the release of FPSOnline 2.0, an updated version of its ... weeklong conferences , La Jolla Government Contracts Week, were given a “sneak peek” ...
(Date:5/21/2019)... ... May 21, 2019 , ... If a ... know? How can we tell it apart from the millions of microorganisms that ... multi-institution research team, including Eric Young , assistant professor of chemical engineering ...
(Date:5/21/2019)... Ariz. (PRWEB) , ... May 20, 2019 , ... ... a recent acclaimed documentary. The documentary, Stem Cell Therapy: Biotechnology to the Rescue, was ... an hour long, Dr. Greene was interviewed in regards to the safety of the ...
Breaking Biology News(10 mins):